Preduprezhdenie tromboembolii u bol'nykh fibrillyatsiey predserdiy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review presents new data on the efficacy and safety of use of acetylsalicylic acid, warfarin, dabigatran, rivaroxaban, and apixaban for the prevention of thromboembolism in patients with atrial fibrillation. Taking into account the results of large randomized clinical trials, it can be argued that the new anticoagulants are preferable for the vast majority of patients with non-valvular atrial fibrillation compared with warfarin, because they provide better efficiency, safety and convenience of treatment. At the same time, the new anticoagulants can not yet compete with warfarin for patients with mechanical heart valves.

Full Text

Restricted Access

About the authors

S. G Kanorskiy

Email: kanorskysg@mail.ru

References

  1. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21): 2719-47.
  2. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15(4):486-93.
  3. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57(11):e101-98.
  4. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke 2009;40(6):2068-72.
  5. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31(8):967-75.
  6. Camm AJ, Kirchhof P Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010;31(19):2369-429.
  7. Turagam MK, Velagapudi P Leal MA, Kocheril AG. Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease. An era of new anticoagulants. Expert Rev Cardiovasc Ther 2012;10(4):433-39.
  8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67.
  9. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15(3):244-52.
  10. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventative drugs declines rapidly during the first two years after stroke. Stroke 2010;41(2):397-401.
  11. Heidbuchel H, Verhamme P Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51.
  12. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013 Apr 2 [Epub ahead of print].
  13. Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12): 1139-51.
  14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.
  15. Connolly SJ, Eikelboom J, Joyner C, Diener HC, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17.
  16. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11):981-92.
  17. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation with Factor Xa Next Generation in Atrialfibrillation-Thrombolysis in Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160(4):635-41.
  18. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.
  19. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123(2):131-36.
  20. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013 Apr 3 [Epub ahead of print].
  21. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012;163(6): 931-37.
  22. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in «real world» patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013 Apr 2 [Epub ahead of print].
  23. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368(14): 1272-74.
  24. Berger R, Salhanick SD, Chase M, Ganetsky M. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013;61(4):475-79.
  25. Food and Drug Administration FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa. Viewed January 2013.http://www.fda.gov/ Drugs/DrugSafety/ucm326580.htm
  26. European Medicines Agency. Safety update of centrally authorised medicine: Pradaxa. Adopted at the CHMP meeting of 21-24 May 2012. Viewed January 2013.http://www.ema.europa. eu/ema/index.jsp?curl=pages/news_and_ events/news/2012/05/news_detail_001518. jsp&mid=WC0b01ac058004d5c1
  27. Australian Government. Therapeutic Goods Administration. Dabigatran (Pradaxa) safety update: Information for consumers. http:// www.tga.gov.au/safety/alerts-medicine-dabigatran-130208.htm

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies